HIMSS survey on Direct identifies use, challenges

Health information organizations are using Direct messaging in support of care coordination use cases but there is great variability in the method of access.  Those are the findings of the HIMSS Interoperability and HIE Committees who conducted a nationwide survey on Direct messaging to learn how the marketplace is using it to facilitate health information exchange (HIE). Direct messaging was intended to increase interoperability, and this survey was intended to provide visibility on its use and value.

Other themes to emerge from the survey include continued challenges incorporating structured data into the EHR, extensive membership in a HISP, some knowledge of the availability of Direct messaging among the clinician community and that most participating organizations support Direct as the method choice for exchanging data.

In a release, the committees said they "see significant progress and optimism in several areas, signaling that HIE is maturing in the marketplace and beginning to deliver the intended value to their providers and communities."

The top five reported uses of Direct include: transitions of care, ADT notifications, patient communication, secure email for other purposes and consult requests between physicians. The top three reported benefits of using Direct include improved speed of information access, reduce paper handing, more accurate and complete patient information.

Major challenges impacting Direct implementations include high cost, changing workflows and other providers not ready to interface.

Seventy-six percent of respondents reported access to a provider directory, a further 64 percent report they can access internal providers from that directory from within their EHR, whereas 52 percent report they can access external providers within their EHR.

Just over half (51 percent) agree that the cost of using Direct is worth the benefit of information exchange.

Access the complete survey results.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.